Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison of Blood Pressure Medications on Metabolism

This study has been completed.
Information provided by (Responsible Party):
Kathleen Colleran, University of New Mexico Identifier:
First received: March 21, 2008
Last updated: August 24, 2011
Last verified: August 2011

The purpose of this study is to determine if there are differences, (benefits) between carvedilol and metoprolol in the treatment of HTN in patients with type 2 diabetes. Specifically we will be looking at differences in blood pressure and blood sugar control, endothelial function, inflammation, oxidative stress and coagulation.

Subjects will be randomized to one of the two beta-blockers and followed for 5 months. Each subject will undergo 4 inpatient studies where an oral glucose tolerance test will be done, Inflammatory and oxidative stress markers will be measured. Endothelial function will be measured using brachial artery ultrasound and laser skin Doppler

Condition Intervention Phase
Drug: carvedilol
Drug: metoprolol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Carvedilol vs.Metoprolol: A Comparison of Effects on Endothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients With Type 2 Diabetes and Hypertension

Resource links provided by NLM:

Further study details as provided by University of New Mexico:

Primary Outcome Measures:
  • change in endothelial function [ Time Frame: 5 months ] [ Designated as safety issue: No ]

Enrollment: 21
Study Start Date: January 2004
Study Completion Date: July 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
study drug
Drug: carvedilol
Active Comparator: 2
study drug
Drug: metoprolol


Ages Eligible for Study:   45 Years to 85 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • not enrolling

Exclusion Criteria:

  • not enrolling
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00642434

United States, New Mexico
Albquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
  More Information

Responsible Party: Kathleen Colleran, Professor of Medicine, University of New Mexico Identifier: NCT00642434     History of Changes
Other Study ID Numbers: UNM04094 
Study First Received: March 21, 2008
Last Updated: August 24, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of New Mexico:
diabetes blood pressure oxidative stress

Additional relevant MeSH terms:
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists processed this record on October 27, 2016